<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03655405</url>
  </required_header>
  <id_info>
    <org_study_id>OLD-NH-IDeI-2018</org_study_id>
    <nct_id>NCT03655405</nct_id>
  </id_info>
  <brief_title>Randomised, Controlled Trial of an Individual Deprescribing Intervention for Nursing Homes Residents</brief_title>
  <acronym>OLD-NH-IDeI</acronym>
  <official_title>Opportunities and Limits to Deprescribing in Nursing Homes: Randomised, Controlled Trial of an Individual Deprescribing Intervention for Nursing Homes Residents.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anne Niquille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Geneva, Switzerland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the effects of a pharmacist-led, deprescribing-focused medication&#xD;
      review on the use of inappropriate medications by nursing home residents&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Nursing home residents are often prescribed inappropriate medication, drugs whose negative&#xD;
      effects outweigh potential benefits or which are not useful anymore. Inappropriate medication&#xD;
      have been linked with worse health outcomes, hospitalisations and death. Deprescribing, the&#xD;
      structured process of withdrawing or tapering inappropriate medications, has been studied as&#xD;
      a potential solution to this problem.&#xD;
&#xD;
      In this study, nursing home residents living in institution which are already engaged in a&#xD;
      deprescribing process will be randomly allocated to receive a medication review or usual&#xD;
      care. The medication review will be performed by the nursing home pharmacist an its results&#xD;
      will be discussed with the responsible physicians and nurses to create a deprescribing plan&#xD;
      specifically tailored to the needs of the resident.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 30, 2018</start_date>
  <completion_date type="Actual">August 22, 2019</completion_date>
  <primary_completion_date type="Actual">August 22, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Inappropriate Medication at Follow-up</measure>
    <time_frame>4 months</time_frame>
    <description>Number of inappropriate medications prescribed at follow-up, assessed using the French translation of STOPP v2.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Potentially Inappropriate DDDs Prescribed to Participants at Follow-up</measure>
    <time_frame>4 months</time_frame>
    <description>Appropriateness assessed using the French translation of STOPP v2; DDD defined by WHO.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Chronic Drugs Prescribed to Participants</measure>
    <time_frame>4 months</time_frame>
    <description>Number of Chronic Drugs Prescribed to Participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Chronic DDDs Prescribed to Participants</measure>
    <time_frame>4 months</time_frame>
    <description>Number of chronic DDDs prescribed to participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of New Drugs Prescribed as a Result of the Intervention</measure>
    <time_frame>4 months</time_frame>
    <description>This outcome was not analysed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related Quality of Life</measure>
    <time_frame>4 months</time_frame>
    <description>The EuroQol 5-Dimensions 5-Levels (EQ-5D-5L) tool was used to assess quality of life; this tool includes&#xD;
a visual analog scale, ranging from 0 to 100, 100 indicating &quot;the best health you can imagine&quot; and 0 &quot;the worst health you can imagine&quot;. Higher results indicate an higher quality of life.&#xD;
5 questions, each with 5 possible answers. Using a valuation set, the answers to individual questions were transformed in a numeric index value for each participants, with a maximum of 1 and an infinitely low minimum. Higher values indicates higher perceived health-related quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Common Drug-related Complaints at Follow-up</measure>
    <time_frame>4 months</time_frame>
    <description>Number of common drug-related complaints at follow-up</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Deaths</measure>
    <time_frame>4 months</time_frame>
    <description>Number of deaths</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants Hospitalized</measure>
    <time_frame>4 months</time_frame>
    <description>Number of participants hospitalized at any time during the study</description>
  </other_outcome>
  <other_outcome>
    <measure>Days Spent in Hospital</measure>
    <time_frame>4 months</time_frame>
    <description>Average number of days spent in hospital during the study period</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Falls Per Participant</measure>
    <time_frame>4 months</time_frame>
    <description>Average number of falls during the study period</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants Who Fell</measure>
    <time_frame>4 months</time_frame>
    <description>Number of participants who fell at least once during the study period</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Falls in Participants That Fell at Least Once</measure>
    <time_frame>4 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of Days Spent With Physical Restraints</measure>
    <time_frame>4 months</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Polypharmacy</condition>
  <condition>Inappropriate Prescribing</condition>
  <arm_group>
    <arm_group_label>Individual Deprescribing Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants allocated to the intervention arm will receive the Individual Deprescribing Intervention (pharmacist-led medication review, followed by the creation of a deprescribing plan by the pharmacist, physician and responsible nurse).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants allocated to the control group will receive usual care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Individual Deprescribing Intervention</intervention_name>
    <description>The pharmacist responsible for the nursing home will perform a medication review (type 3). The results of this review will be discussed with the physician and nurse responsible for this participant, with the goal of creating a personalised deprescribing plan. Once validated by the physician, this plan will be submitted to the participant for approval.</description>
    <arm_group_label>Individual Deprescribing Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Take 5 or more prescribed drugs daily;&#xD;
&#xD;
          -  Reside in the Nursing Home since at least 4 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Physician judges that discussing deprescribing with them risks destabilising them.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier Bugnon, Prof</last_name>
    <role>Study Director</role>
    <affiliation>ISPSO, Universties of Geneva and Lausanne, Switzerland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre de Pharmacie Communautaire</name>
      <address>
        <city>Lausanne</city>
        <state>Vaud</state>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>http://www.nfp74.ch/fr/projets/soins-stationnaires/projet-bugnon</url>
    <description>Project description on the funding body website</description>
  </link>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>August 30, 2018</study_first_submitted>
  <study_first_submitted_qc>August 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2018</study_first_posted>
  <results_first_submitted>November 10, 2020</results_first_submitted>
  <results_first_submitted_qc>April 28, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 19, 2021</results_first_posted>
  <last_update_submitted>April 28, 2021</last_update_submitted>
  <last_update_submitted_qc>April 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Geneva, Switzerland</investigator_affiliation>
    <investigator_full_name>Anne Niquille</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <keyword>Deprescribing</keyword>
  <keyword>Nursing Home</keyword>
  <keyword>Potentially Inappropriate Medication</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data are available from the investigators upon reasonable request.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>10-year availability</ipd_time_frame>
    <ipd_access_criteria>Data are available from the investigators upon reasonable request.</ipd_access_criteria>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 27, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/05/NCT03655405/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Individual Deprescribing Intervention</title>
          <description>Participants allocated to the intervention arm will receive the Individual Deprescribing Intervention (pharmacist-led medication review, followed by the creation of a deprescribing plan by the pharmacist, physician and responsible nurse).&#xD;
Individual Deprescribing Intervention: The pharmacist responsible for the nursing home will perform a medication review (type 3). The results of this review will be discussed with the physician and nurse responsible for this participant, with the goal of creating a personalised deprescribing plan. Once validated by the physician, this plan will be submitted to the participant for approval.</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
          <description>Participants allocated to the control group will receive usual care.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death after initial data collection</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Died before initial data collection</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intervention: 1 participant excluded, died before initial data collection; Control: 3 participants excluded: 2 died before initial data collection, no data was collected on one.</population>
      <group_list>
        <group group_id="B1">
          <title>Individual Deprescribing Intervention</title>
          <description>Participants allocated to the intervention arm will receive the Individual Deprescribing Intervention (pharmacist-led medication review, followed by the creation of a deprescribing plan by the pharmacist, physician and responsible nurse).&#xD;
Individual Deprescribing Intervention: The pharmacist responsible for the nursing home will perform a medication review (type 3). The results of this review will be discussed with the physician and nurse responsible for this participant, with the goal of creating a personalised deprescribing plan. Once validated by the physician, this plan will be submitted to the participant for approval.</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>Participants allocated to the control group will receive usual care.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="31"/>
            <count group_id="B2" value="27"/>
            <count group_id="B3" value="58"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="31"/>
                    <count group_id="B2" value="27"/>
                    <count group_id="B3" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="87" lower_limit="80" upper_limit="91"/>
                    <measurement group_id="B2" value="84" lower_limit="78" upper_limit="88"/>
                    <measurement group_id="B3" value="87" lower_limit="80" upper_limit="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="31"/>
                    <count group_id="B2" value="27"/>
                    <count group_id="B3" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Switzerland</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="31"/>
                    <count group_id="B2" value="27"/>
                    <count group_id="B3" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of stay in years</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="31"/>
                    <count group_id="B2" value="27"/>
                    <count group_id="B3" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.1" spread="2.3"/>
                    <measurement group_id="B2" value="3.6" spread="3.6"/>
                    <measurement group_id="B3" value="3.4" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of drugs prescribed</title>
          <units>drugs</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="31"/>
                    <count group_id="B2" value="27"/>
                    <count group_id="B3" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15" lower_limit="12" upper_limit="19"/>
                    <measurement group_id="B2" value="15" lower_limit="13" upper_limit="18"/>
                    <measurement group_id="B3" value="15" lower_limit="12" upper_limit="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of chronic drugs</title>
          <units>drugs</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="31"/>
                    <count group_id="B2" value="27"/>
                    <count group_id="B3" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12" lower_limit="10" upper_limit="14"/>
                    <measurement group_id="B2" value="11" lower_limit="8" upper_limit="12"/>
                    <measurement group_id="B3" value="11" lower_limit="9" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of PIMs</title>
          <description>Number of Potentially Inappropriate Medications (PIMs); appropriateness is assessed using the French translation of the Screening Tool of Older People's Prescription (STOPP) v2.</description>
          <units>potentially inappropriate medications</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="31"/>
                    <count group_id="B2" value="27"/>
                    <count group_id="B3" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5" lower_limit="4" upper_limit="7"/>
                    <measurement group_id="B2" value="6" lower_limit="3" upper_limit="7"/>
                    <measurement group_id="B3" value="5" lower_limit="3" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of chronic DDDs</title>
          <description>Number of chronic Defined Daily Dose (DDD); chronicity is defined as the absence of a planned cessation date in the participant's record. DDDs are assigned according the the World Health Organization's (WHO) DDD set.</description>
          <units>chronic DDD</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="31"/>
                    <count group_id="B2" value="27"/>
                    <count group_id="B3" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.6" spread="3.5"/>
                    <measurement group_id="B2" value="9.3" spread="3.6"/>
                    <measurement group_id="B3" value="9.5" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of PIM DDDs</title>
          <description>Sum of potentially inappropriate DDDs; appropriateness is assessed using the French translation of STOPP v2; DDDs are assigned according to the WHO's DDD set.</description>
          <units>PIM DDD</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="31"/>
                    <count group_id="B2" value="27"/>
                    <count group_id="B3" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.6" spread="2.8"/>
                    <measurement group_id="B2" value="3.4" spread="2.1"/>
                    <measurement group_id="B3" value="3.5" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Quality of life: EQ-5D-5L analog scale</title>
          <description>The EuroQol 5-Dimensions 5-Levels (EQ-5D-5L) tool was used to assess quality of life; this tool includes a visual analog scale, ranging from 0 to 100, 100 indicating &quot;the best health you can imagine&quot; and 0 &quot;the worst health you can imagine&quot;. Higher results indicate an higher quality of life.</description>
          <units>analog scale units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="31"/>
                    <count group_id="B2" value="27"/>
                    <count group_id="B3" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.5" spread="24.8"/>
                    <measurement group_id="B2" value="61.4" spread="20.5"/>
                    <measurement group_id="B3" value="58.9" spread="22.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Quality of life: EQ-5D-5L index</title>
          <description>The quality of life was assessed using EQ-5D-5L; this tool includes 5 questions, each with 5 possible answers. Using a valuation set, the answers to individual questions were transformed in a numeric index value for each participants, with a maximum of 1 and an infinitely low minimum. Higher values indicates higher perceived health-related quality of life.</description>
          <units>index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="31"/>
                    <count group_id="B2" value="27"/>
                    <count group_id="B3" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.46" spread="0.34"/>
                    <measurement group_id="B2" value="0.50" spread="0.33"/>
                    <measurement group_id="B3" value="0.48" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Inappropriate Medication at Follow-up</title>
        <description>Number of inappropriate medications prescribed at follow-up, assessed using the French translation of STOPP v2.</description>
        <time_frame>4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Individual Deprescribing Intervention</title>
            <description>Participants allocated to the intervention arm will receive the Individual Deprescribing Intervention (pharmacist-led medication review, followed by the creation of a deprescribing plan by the pharmacist, physician and responsible nurse).&#xD;
Individual Deprescribing Intervention: The pharmacist responsible for the nursing home will perform a medication review (type 3). The results of this review will be discussed with the physician and nurse responsible for this participant, with the goal of creating a personalised deprescribing plan. Once validated by the physician, this plan will be submitted to the participant for approval.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Participants allocated to the control group will receive usual care.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Inappropriate Medication at Follow-up</title>
          <description>Number of inappropriate medications prescribed at follow-up, assessed using the French translation of STOPP v2.</description>
          <units>drugs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.35" spread="2.72"/>
                    <measurement group_id="O2" value="4.85" spread="2.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.723</p_value>
            <method>Regression, Poisson</method>
            <method_desc>Number of PIMs at follow-up, adjusted for baseline value</method_desc>
            <param_type>Incidence Rate Ratio</param_type>
            <param_value>0.972</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.830</ci_lower_limit>
            <ci_upper_limit>1.138</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Potentially Inappropriate DDDs Prescribed to Participants at Follow-up</title>
        <description>Appropriateness assessed using the French translation of STOPP v2; DDD defined by WHO.</description>
        <time_frame>4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Individual Deprescribing Intervention</title>
            <description>Participants allocated to the intervention arm will receive the Individual Deprescribing Intervention (pharmacist-led medication review, followed by the creation of a deprescribing plan by the pharmacist, physician and responsible nurse).&#xD;
Individual Deprescribing Intervention: The pharmacist responsible for the nursing home will perform a medication review (type 3). The results of this review will be discussed with the physician and nurse responsible for this participant, with the goal of creating a personalised deprescribing plan. Once validated by the physician, this plan will be submitted to the participant for approval.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Participants allocated to the control group will receive usual care.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Potentially Inappropriate DDDs Prescribed to Participants at Follow-up</title>
          <description>Appropriateness assessed using the French translation of STOPP v2; DDD defined by WHO.</description>
          <units>DDD</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.73" spread="2.97"/>
                    <measurement group_id="O2" value="3.10" spread="1.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.033</p_value>
            <method>Regression, Poisson</method>
            <method_desc>Number of potentially inappropriate DDD at follow-up, adjusted for baseline value</method_desc>
            <param_type>Incidence Rate Ratio</param_type>
            <param_value>0.763</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.594</ci_lower_limit>
            <ci_upper_limit>0.979</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Chronic Drugs Prescribed to Participants</title>
        <description>Number of Chronic Drugs Prescribed to Participants</description>
        <time_frame>4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Individual Deprescribing Intervention</title>
            <description>Participants allocated to the intervention arm will receive the Individual Deprescribing Intervention (pharmacist-led medication review, followed by the creation of a deprescribing plan by the pharmacist, physician and responsible nurse).&#xD;
Individual Deprescribing Intervention: The pharmacist responsible for the nursing home will perform a medication review (type 3). The results of this review will be discussed with the physician and nurse responsible for this participant, with the goal of creating a personalised deprescribing plan. Once validated by the physician, this plan will be submitted to the participant for approval.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Participants allocated to the control group will receive usual care.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Chronic Drugs Prescribed to Participants</title>
          <description>Number of Chronic Drugs Prescribed to Participants</description>
          <units>drugs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.68" spread="3.59"/>
                    <measurement group_id="O2" value="9.67" spread="3.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.064</p_value>
            <method>Regression, Poisson</method>
            <method_desc>Number of chronic drugs at follow-up, adjusted for baseline value</method_desc>
            <param_type>Incidence Rate Ratio</param_type>
            <param_value>0.915</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.834</ci_lower_limit>
            <ci_upper_limit>1.005</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Chronic DDDs Prescribed to Participants</title>
        <description>Number of chronic DDDs prescribed to participants</description>
        <time_frame>4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Individual Deprescribing Intervention</title>
            <description>Participants allocated to the intervention arm will receive the Individual Deprescribing Intervention (pharmacist-led medication review, followed by the creation of a deprescribing plan by the pharmacist, physician and responsible nurse).&#xD;
Individual Deprescribing Intervention: The pharmacist responsible for the nursing home will perform a medication review (type 3). The results of this review will be discussed with the physician and nurse responsible for this participant, with the goal of creating a personalised deprescribing plan. Once validated by the physician, this plan will be submitted to the participant for approval.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Participants allocated to the control group will receive usual care.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Chronic DDDs Prescribed to Participants</title>
          <description>Number of chronic DDDs prescribed to participants</description>
          <units>DDD</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.82" spread="3.85"/>
                    <measurement group_id="O2" value="7.65" spread="2.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.857</p_value>
            <method>Regression, Poisson</method>
            <method_desc>Number of chronic drugs at follow-up, adjusted for baseline value</method_desc>
            <param_type>Incidence Rate Ratio</param_type>
            <param_value>1.019</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.833</ci_lower_limit>
            <ci_upper_limit>1.246</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of New Drugs Prescribed as a Result of the Intervention</title>
        <description>This outcome was not analysed</description>
        <time_frame>4 months</time_frame>
        <population>This outcome was not analyzed, as the drugs newly prescribed as a result of the intervention could not be distinguished from the other drugs newly prescribed.</population>
        <group_list>
          <group group_id="O1">
            <title>Individual Deprescribing Intervention</title>
            <description>Participants allocated to the intervention arm will receive the Individual Deprescribing Intervention (pharmacist-led medication review, followed by the creation of a deprescribing plan by the pharmacist, physician and responsible nurse).&#xD;
Individual Deprescribing Intervention: The pharmacist responsible for the nursing home will perform a medication review (type 3). The results of this review will be discussed with the physician and nurse responsible for this participant, with the goal of creating a personalised deprescribing plan. Once validated by the physician, this plan will be submitted to the participant for approval.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Participants allocated to the control group will receive usual care.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of New Drugs Prescribed as a Result of the Intervention</title>
          <description>This outcome was not analysed</description>
          <population>This outcome was not analyzed, as the drugs newly prescribed as a result of the intervention could not be distinguished from the other drugs newly prescribed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health-related Quality of Life</title>
        <description>The EuroQol 5-Dimensions 5-Levels (EQ-5D-5L) tool was used to assess quality of life; this tool includes&#xD;
a visual analog scale, ranging from 0 to 100, 100 indicating &quot;the best health you can imagine&quot; and 0 &quot;the worst health you can imagine&quot;. Higher results indicate an higher quality of life.&#xD;
5 questions, each with 5 possible answers. Using a valuation set, the answers to individual questions were transformed in a numeric index value for each participants, with a maximum of 1 and an infinitely low minimum. Higher values indicates higher perceived health-related quality of life.</description>
        <time_frame>4 months</time_frame>
        <population>Data on this outcome were missing for some participants</population>
        <group_list>
          <group group_id="O1">
            <title>Individual Deprescribing Intervention</title>
            <description>Participants allocated to the intervention arm will receive the Individual Deprescribing Intervention (pharmacist-led medication review, followed by the creation of a deprescribing plan by the pharmacist, physician and responsible nurse).&#xD;
Individual Deprescribing Intervention: The pharmacist responsible for the nursing home will perform a medication review (type 3). The results of this review will be discussed with the physician and nurse responsible for this participant, with the goal of creating a personalised deprescribing plan. Once validated by the physician, this plan will be submitted to the participant for approval.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Participants allocated to the control group will receive usual care.</description>
          </group>
        </group_list>
        <measure>
          <title>Health-related Quality of Life</title>
          <description>The EuroQol 5-Dimensions 5-Levels (EQ-5D-5L) tool was used to assess quality of life; this tool includes&#xD;
a visual analog scale, ranging from 0 to 100, 100 indicating &quot;the best health you can imagine&quot; and 0 &quot;the worst health you can imagine&quot;. Higher results indicate an higher quality of life.&#xD;
5 questions, each with 5 possible answers. Using a valuation set, the answers to individual questions were transformed in a numeric index value for each participants, with a maximum of 1 and an infinitely low minimum. Higher values indicates higher perceived health-related quality of life.</description>
          <population>Data on this outcome were missing for some participants</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>EQ-5D-5L scale</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.5" spread="17.2"/>
                    <measurement group_id="O2" value="65.4" spread="22.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EQ-5D-l index</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.51" spread="0.31"/>
                    <measurement group_id="O2" value="0.61" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis for the scale component</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.769</p_value>
            <method>Regression, Linear</method>
            <method_desc>Scale value at follow-up, adjusted for baseline value</method_desc>
            <param_type>Slope</param_type>
            <param_value>-1.36</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.60</ci_lower_limit>
            <ci_upper_limit>7.89</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis for the index component</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.075</p_value>
            <method>Regression, Linear</method>
            <method_desc>Scale value at follow-up, adjusted for baseline value</method_desc>
            <param_type>Slope</param_type>
            <param_value>-0.096</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.202</ci_lower_limit>
            <ci_upper_limit>0.01</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Common Drug-related Complaints at Follow-up</title>
        <description>Number of common drug-related complaints at follow-up</description>
        <time_frame>4 months</time_frame>
        <population>Data on this outcome at follow-up were missing for some participants, because of death or hospitalisation.</population>
        <group_list>
          <group group_id="O1">
            <title>Individual Deprescribing Intervention</title>
            <description>Participants allocated to the intervention arm will receive the Individual Deprescribing Intervention (pharmacist-led medication review, followed by the creation of a deprescribing plan by the pharmacist, physician and responsible nurse).&#xD;
Individual Deprescribing Intervention: The pharmacist responsible for the nursing home will perform a medication review (type 3). The results of this review will be discussed with the physician and nurse responsible for this participant, with the goal of creating a personalised deprescribing plan. Once validated by the physician, this plan will be submitted to the participant for approval.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Participants allocated to the control group will receive usual care.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Common Drug-related Complaints at Follow-up</title>
          <description>Number of common drug-related complaints at follow-up</description>
          <population>Data on this outcome at follow-up were missing for some participants, because of death or hospitalisation.</population>
          <units>Number of complaints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.35" spread="2.60"/>
                    <measurement group_id="O2" value="1.44" spread="1.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.212</p_value>
            <method>Mixed-effect regression, Poisson</method>
            <method_desc>Number at follow-up, adjusted for baseline value</method_desc>
            <param_type>Incidence Rate Ratio</param_type>
            <param_value>1.237</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.886</ci_lower_limit>
            <ci_upper_limit>1.727</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Deaths</title>
        <description>Number of deaths</description>
        <time_frame>4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Individual Deprescribing Intervention</title>
            <description>Participants allocated to the intervention arm will receive the Individual Deprescribing Intervention (pharmacist-led medication review, followed by the creation of a deprescribing plan by the pharmacist, physician and responsible nurse).&#xD;
Individual Deprescribing Intervention: The pharmacist responsible for the nursing home will perform a medication review (type 3). The results of this review will be discussed with the physician and nurse responsible for this participant, with the goal of creating a personalised deprescribing plan. Once validated by the physician, this plan will be submitted to the participant for approval.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Participants allocated to the control group will receive usual care.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Deaths</title>
          <description>Number of deaths</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.675</p_value>
            <method>Fisher Exact</method>
            <param_type>p-value</param_type>
            <param_value>0.675</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants Hospitalized</title>
        <description>Number of participants hospitalized at any time during the study</description>
        <time_frame>4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Individual Deprescribing Intervention</title>
            <description>Participants allocated to the intervention arm will receive the Individual Deprescribing Intervention (pharmacist-led medication review, followed by the creation of a deprescribing plan by the pharmacist, physician and responsible nurse).&#xD;
Individual Deprescribing Intervention: The pharmacist responsible for the nursing home will perform a medication review (type 3). The results of this review will be discussed with the physician and nurse responsible for this participant, with the goal of creating a personalised deprescribing plan. Once validated by the physician, this plan will be submitted to the participant for approval.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Participants allocated to the control group will receive usual care.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Hospitalized</title>
          <description>Number of participants hospitalized at any time during the study</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.615</p_value>
            <method>Fisher Exact</method>
            <param_type>p-value</param_type>
            <param_value>0.615</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Days Spent in Hospital</title>
        <description>Average number of days spent in hospital during the study period</description>
        <time_frame>4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Individual Deprescribing Intervention</title>
            <description>Participants allocated to the intervention arm will receive the Individual Deprescribing Intervention (pharmacist-led medication review, followed by the creation of a deprescribing plan by the pharmacist, physician and responsible nurse).&#xD;
Individual Deprescribing Intervention: The pharmacist responsible for the nursing home will perform a medication review (type 3). The results of this review will be discussed with the physician and nurse responsible for this participant, with the goal of creating a personalised deprescribing plan. Once validated by the physician, this plan will be submitted to the participant for approval.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Participants allocated to the control group will receive usual care.</description>
          </group>
        </group_list>
        <measure>
          <title>Days Spent in Hospital</title>
          <description>Average number of days spent in hospital during the study period</description>
          <units>Number of days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="15.8"/>
                    <measurement group_id="O2" value="0.6" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.366</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>p-value</param_type>
            <param_value>0.366</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Falls Per Participant</title>
        <description>Average number of falls during the study period</description>
        <time_frame>4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Individual Deprescribing Intervention</title>
            <description>Participants allocated to the intervention arm will receive the Individual Deprescribing Intervention (pharmacist-led medication review, followed by the creation of a deprescribing plan by the pharmacist, physician and responsible nurse).&#xD;
Individual Deprescribing Intervention: The pharmacist responsible for the nursing home will perform a medication review (type 3). The results of this review will be discussed with the physician and nurse responsible for this participant, with the goal of creating a personalised deprescribing plan. Once validated by the physician, this plan will be submitted to the participant for approval.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Participants allocated to the control group will receive usual care.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Falls Per Participant</title>
          <description>Average number of falls during the study period</description>
          <units>falls</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.45" spread="0.89"/>
                    <measurement group_id="O2" value="0.48" spread="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.738</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>p-value</param_type>
            <param_value>0.738</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants Who Fell</title>
        <description>Number of participants who fell at least once during the study period</description>
        <time_frame>4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Individual Deprescribing Intervention</title>
            <description>Participants allocated to the intervention arm will receive the Individual Deprescribing Intervention (pharmacist-led medication review, followed by the creation of a deprescribing plan by the pharmacist, physician and responsible nurse).&#xD;
Individual Deprescribing Intervention: The pharmacist responsible for the nursing home will perform a medication review (type 3). The results of this review will be discussed with the physician and nurse responsible for this participant, with the goal of creating a personalised deprescribing plan. Once validated by the physician, this plan will be submitted to the participant for approval.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Participants allocated to the control group will receive usual care.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Fell</title>
          <description>Number of participants who fell at least once during the study period</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.781</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>p-value</param_type>
            <param_value>0.781</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Falls in Participants That Fell at Least Once</title>
        <time_frame>4 months</time_frame>
        <population>Only the participants who fell at least once were included in this analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Individual Deprescribing Intervention</title>
            <description>Participants allocated to the intervention arm will receive the Individual Deprescribing Intervention (pharmacist-led medication review, followed by the creation of a deprescribing plan by the pharmacist, physician and responsible nurse).&#xD;
Individual Deprescribing Intervention: The pharmacist responsible for the nursing home will perform a medication review (type 3). The results of this review will be discussed with the physician and nurse responsible for this participant, with the goal of creating a personalised deprescribing plan. Once validated by the physician, this plan will be submitted to the participant for approval.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Participants allocated to the control group will receive usual care.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Falls in Participants That Fell at Least Once</title>
          <population>Only the participants who fell at least once were included in this analysis</population>
          <units>Number of falls</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="1.0"/>
                    <measurement group_id="O2" value="1.4" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.958</p_value>
            <method>Fisher Exact</method>
            <param_type>p-value</param_type>
            <param_value>0.958</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Days Spent With Physical Restraints</title>
        <time_frame>4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Individual Deprescribing Intervention</title>
            <description>Participants allocated to the intervention arm will receive the Individual Deprescribing Intervention (pharmacist-led medication review, followed by the creation of a deprescribing plan by the pharmacist, physician and responsible nurse).&#xD;
Individual Deprescribing Intervention: The pharmacist responsible for the nursing home will perform a medication review (type 3). The results of this review will be discussed with the physician and nurse responsible for this participant, with the goal of creating a personalised deprescribing plan. Once validated by the physician, this plan will be submitted to the participant for approval.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Participants allocated to the control group will receive usual care.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days Spent With Physical Restraints</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.6" spread="39.1"/>
                    <measurement group_id="O2" value="15.1" spread="39.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.911</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>p-value</param_type>
            <param_value>0.911</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 months</time_frame>
      <desc>Adverse events were collected for the intervention group only.</desc>
      <group_list>
        <group group_id="E1">
          <title>0.911 0.911 Individual Deprescribing Intervention</title>
          <description>Participants allocated to the intervention arm will receive the Individual Deprescribing Intervention (pharmacist-led medication review, followed by the creation of a deprescribing plan by the pharmacist, physician and responsible nurse).&#xD;
Individual Deprescribing Intervention: The pharmacist responsible for the nursing home will perform a medication review (type 3). The results of this review will be discussed with the physician and nurse responsible for this participant, with the goal of creating a personalised deprescribing plan. Once validated by the physician, this plan will be submitted to the participant for approval.</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
          <description>Participants allocated to the control group will receive usual care.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hematemesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Gout crisis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Anne Niquille</name_or_title>
      <organization>a. Community Pharmacy, Center for Primary Care and Public Health (Unisanté), University of Lausanne, Switzerland</organization>
      <phone>+41213144845</phone>
      <email>anne.niquille@unisante.ch</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

